ストックスクリーナーアプリを入手
0.8452
1.86%
-0.016
Metagenomi Therapeutics Inc (MGX) 最新ニュース
Metagenomi Therapeutics Submits September 2026 Corporate Presentation to SEC Under Regulation FD - Kalkine Media
TScan Therapeutics (Nasdaq:TCRX)Stock Analysis - simplywall.st
Metagenomi director Laurence Reid buys $23,401 in company stock By Investing.com - Investing.com South Africa
Metagenomi director Laurence Reid buys $23,401 in company stock - Investing.com
Metagenomi director Laurence Reid buys $23,401 in company stock By Investing.com - Investing.com Canada
Metagenomi director Laurence Reid buys $23,401 in company stock By Investing.com - Investing.com Australia
Metagenomi director Laurence Reid buys $23,401 in company stock - Investing.com
Director buys 20,000 Metagenomi Therapeutics (MGX) shares in open-market deal - stocktitan.net
Metagenomi (MGX) counsel’s tax sale covers RSU vesting - stocktitan.net
Automatic tax sale trims Metagenomi (MGX) CEO stake - stocktitan.net
Metagenomi general counsel Matthew Wein sells $414 in stock - Investing.com
Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock - Investing.com
A 7.3% slice of Metagenomi Therapeutics (MGX) is held by one investor - Stock Titan
Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock By Investing.com - Investing.com UK
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference - Barchart.com
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference - manilatimes.net
Metagenomi, Inc. Common Stock (NASDAQ: MGX) Share Price, MGX Stock News, MGX Share Price & Updates - Kalkine
Metagenomi, Inc. Common Stock (NASDAQ: MGX) Share Price, MGX Stock News, MGX Share Price & Updates - kalkine.ca
MGX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Gene Editing Cash BurnRevenue Per Share - careplusvn.com
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Metagenomi Therapeutics (NasdaqGS:MGX) Stock Forecast & Analyst Predictions - Simply Wall Street
Metagenomi Therapeutics (MGX) Holds Flat at $1.23 as Gene-Editing Stock Consolidates Between Support and ResistanceAAII Bullish - careplusvn.com
Metagenomi Therapeutics (MGX) Holds Flat at $1.23 as Gene-Editing Stock Consolidates Between Support and ResistanceOversold Bounce Ideas - dars.gov.et
Metagenomi Therapeutics (MGX) Holds Steady at $1.23 as Biotech Consolidates Between Key LevelsBreakout Stock Alerts - vinanet.vn
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - webull.com
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - simplywall.st
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Metagenomi Therapeutics reports $27.5M loss in Q2 2026 - scanx.trade
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Metagenomi Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - AOL.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - kens5.com
Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M - Stock Titan
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - Yahoo Finance
Metagenomi Therapeutics 2Q 2026: Revenue $(0.3)M, EPS $(0.73) — 10-Q Summary - TradingView
Metagenomi Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Metagenomi Therapeutics (MGX) Edges Lower to $1.23 as Gene-Editing Stock Tests Key Technical RangeUnusual Put Volume - careplusvn.com
MGX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesQuarterly Earnings - vinanet.vn
Metagenomi Therapeutics (MGX) Edges Higher as Gene-Editing Speculation PercolatesVolume Dry Up - careplusvn.com
Metagenomi Therapeutics (MGX) Edges Higher as Gene-Editing Speculation PercolatesMarket Neutral Pair - dars.gov.et
Amazon has Q2 sales of $200bn - Electronics Weekly
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineManagement Tone Analysis - vinanet.vn
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineAnnual Financial Report - dars.gov.et
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineSaaS Earnings Trends - dars.gov.et
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineEPS Growth Rate - dars.gov.et
Metagenomi Therapeutics, Inc. Revenue Breakdown – NASDAQ:MGX - TradingView
1.35%
大文字化:
|
ボリューム (24 時間):